Who makes RSVpreF + qIRV 0.5 mL formulation?

RSVpreF + qIRV 0.5 mL formulation is developed by Pfizer Inc..

What development phase is RSVpreF + qIRV 0.5 mL formulation in?

RSVpreF + qIRV 0.5 mL formulation is FDA-approved (marketed).

What is the generic name of RSVpreF + qIRV 0.5 mL formulation?

rsvpref-qirv-0-5-ml-formulation is the generic (nonproprietary) name of RSVpreF + qIRV 0.5 mL formulation.

Last reviewed 2026-04-20 · How we verify

RSVpreF + qIRV 0.5 mL formulation (rsvpref-qirv-0-5-ml-formulation)

Pfizer Inc. · FDA-approved active Quality 10/100

At a glance

Generic name	rsvpref-qirv-0-5-ml-formulation
Sponsor	Pfizer Inc.
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Respiratory Combination Vaccine Candidates in Older Adults (Phase 1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

RSVpreF + qIRV 0.5 mL formulation CI brief — competitive landscape report
RSVpreF + qIRV 0.5 mL formulation updates RSS · CI watch RSS
Pfizer Inc. portfolio CI